摘要
目的 了解肾移植患者体内普乐可复 (FK5 0 6 )药代动力学特征 ,为临床制定个体化用药方案提供依据 .方法 采用微粒子酶免分析仪测定用药前后不同时间全血中 FK5 0 6浓度 ,以 3P97药动学程序拟合求算 FK5 0 6药动学参数 .结果 在患者 po FK5 0 6 (9m g/ 12 h)达稳定态后 FK5 0 6在体内处置为一室开放模型 ,药动力学参数 Tmax,ρmax,T1 /2 ke,AUC分别为 1.2 h,75 .3mg· L- 1 ,3.9h和 5 2 6 .6 mg· h· L- 1 ,全血浓度波动差值为 6 3.4mg· L- 1 .结论 为降低 FK5 0 6全血浓度波动范围 ,采用 8h一次 po FK5 0 6更为适宜 ,同时应加强 FK5 0 6血药浓度监测 。
AIM To investigate the clinical pharmacokinetics of tacrolimus (FK506) in a renal transplant recipient and to provide gist for clinical individual dosage. METHODS Whole blood samples were drawn at 15, 45, 60, 90, 120, 240, 360, 480, 720 min after using FK506. Whole blood concentration of FK506 was analyzed by microparticle enzyme immunoassay (MEIA), by fitting the concentration time date with the computer software package 3P97, and the parameters of pharmacokinetics were calculated. RESULTS Compartmental analysis yielded a one compartment open model in the stable state after oral administration FK506 9 mg/12 h. Pharmacokinetics parameters of FK506 for the patient were as follows respectively: T max =1.2 h, ρ max =75.3 mg·L -1 , T 1/2 ke=3.9 h, AUC=526.6 mg·h·L -1 . The fluctuant range of whole blood concentration of FK506 was from 15.0 to 78.4 mg·L -1 . CONCLUSION To reduce the fluctuant range of whole blood concentration of FK506, oral administration of FK506 three times a day is recommended. The whole blood concentration of FK506 should be monitored to ensure safety and efficacy.
出处
《第四军医大学学报》
北大核心
2001年第20期1909-1911,共3页
Journal of the Fourth Military Medical University
关键词
普乐可复
肾移植
药代动力学
免疫抑制剂
tacrolimus
kidney transplantation
pharmacokinetics
immunosuppressive agents
